150 results
Page 4 of 8
8-K
EX-99.1
88515qrs8xoj7wtv9oi
27 Oct 21
Alkermes plc Reports Third Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
l019vq se8yv0
1 Jun 21
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
7:09am
DEFA14A
EX-99.1
asvk 2asgg3r
20 May 21
Additional proxy soliciting materials
7:11am
8-K
EX-99.1
xu0ctr eg96o
20 May 21
Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors
7:10am
DEFA14A
EX-99.1
bydto2z
30 Apr 21
Additional proxy soliciting materials
7:11am
8-K
EX-99.1
l9cr3n riui
30 Apr 21
Alkermes Announces Agreement with Sarissa Capital
7:10am
8-K
EX-99.1
36xc2951155
28 Apr 21
Alkermes plc Reports First Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
2kw4u54
25 Mar 21
Regulation FD Disclosure
12:00am
8-K
EX-99.1
s96r5
11 Feb 21
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
oiqm0ag
11 Jan 21
Regulation FD Disclosure
7:00am
8-K
EX-99.1
00s3dx
6 Jan 21
Alkermes Announces Updates to Executive Leadership Team
4:24pm
8-K
EX-99.1
ap2n1 65hhukz6
10 Dec 20
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
7:19am
8-K
EX-10.1
epl7kz322c x5
10 Dec 20
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
7:19am
8-K
EX-99.1
ik83z
17 Nov 20
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
7:15am
8-K
EX-99.1
y9gwk0 uk
29 Oct 20
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
7:06am
8-K
EX-99.1
vz8ceeay wwv1d6g
9 Oct 20
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
5:20pm